# Type 1 allergic reactions FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/type-1-allergic-reactions

> No upcoming FDA catalysts in type 1 allergic reactions; 3 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for type 1 allergic reactions?

No upcoming FDA catalysts in type 1 allergic reactions; 3 past events are recorded. Press release filed with the SEC (EX-99): "Anaphylm™ (dibutepinephrine) Sublingual Film The Company is in contact with the U.S. Food and Drug Administration (FDA) to gather further information about the deficiencies presently identified by the FDA in the New Drug Application (NDA) for Anaphylm, with the goal of addressing those deficiencies prior to the scheduled PDUFA action date of January 31, 2026, once disclosed to the Company." [Calendar and source filings](https://sec-api.dev/indications/type-1-allergic-reactions)

Source: Press release filed with the SEC (EX-99), accession 0001398733-26-000003, https://www.sec.gov/Archives/edgar/data/1398733/000139873326000003/aquestivepressrelease-fi.htm (retrieved 2026-11-12). Last confirmed 2026-01-09. Cite: https://sec-api.dev/indications/type-1-allergic-reactions#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 9, 2024 | [ARS Pharmaceuticals, Inc. FDA approval](https://sec-api.dev/companies/spry/catalysts) | SPRY | Type 1 allergic reactions | completed, approved | "On August 9, 2024, the FDA approved neffy® (epinephrine nasal spray) 2 mg for the treatment of Type 1 allergic reactions, including anaphylaxis, in adults and children who weigh ≥30 kg (66 lbs.). neffy was first available for shipment on September 23, 2024, and in early October, the U.S. sales force started in the field and neffy became broadly available in retail pharmacies." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000095017024125921/spry-ex99_1.htm)) |
| June 16, 2025 | [Anaphylm™ (dibutepinephrine) NDA/BLA acceptance](https://sec-api.dev/pdufa/dibutepinephrine) | AQST | Type 1 allergic reactions | completed | "FDA assigns PDUFA target action date of January 31, 2026 WARREN, N.J., June 16, 2025 - Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for Anaphylm™ in the treatment of Type 1 allergic reactions, including anaphylaxis, and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000162828025031455/prndaacceptancedraft6-13.htm)) |
| January 31, 2026 | [Anaphylm™ (dibutepinephrine) PDUFA date](https://sec-api.dev/pdufa/dibutepinephrine) | AQST | Type 1 allergic reactions | completed, complete response letter | "Anaphylm™ (dibutepinephrine) Sublingual Film The Company is in contact with the U.S. Food and Drug Administration (FDA) to gather further information about the deficiencies presently identified by the FDA in the New Drug Application (NDA) for Anaphylm, with the goal of addressing those deficiencies prior to the scheduled PDUFA action date of January 31, 2026, once disclosed to the Company." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000003/aquestivepressrelease-fi.htm)) |

## Drugs

- [Anaphylm™ (dibutepinephrine)](https://sec-api.dev/pdufa/dibutepinephrine) (AQST)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/type-1-allergic-reactions.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Type 1 allergic reactions FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/type-1-allergic-reactions

```bibtex
@misc{secapidev_indications_type_1_allergic_reactions_20261116,
  title        = {Type 1 allergic reactions FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/type-1-allergic-reactions}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_type_1_allergic_reactions_20261116","title":"Type 1 allergic reactions FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/type-1-allergic-reactions","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
